This alleviates the need to select for less frequent indel mutations, which is supported by the observation that the frequency of frameshift TP53 mutations in human cancer (10–15%) is similar to the frequency observed in the human genome (Supplementary Fig. S1). This evidence concerns the gene TP53 and cancer.